Breast Cancer: Current Research
Open 91桃色
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open 91桃色 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open 91桃色 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 114
Indexed In
- RefSeek
- Hamdard University
- EBSCO A-Z
- Publons
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
The impact of nolvadex to generic tamoxifen switch on side effects and patient compliance in hormone receptor positive breast cancer patients
5th World Congress on Breast Cancer
Bashar Zeidan, Karen Anderson, Lashan Peiris, Dick Rainsbury and Siobhan Laws
Royal Hampshire County Hospital, England
ScientificTracks Abstracts: Breast Can Curr Res
DOI:
Abstract
Introduction: Adjuvant hormonal therapy in oestrogen receptor (ER) positive breast cancer patients improves survival. In 2006 the original tamoxifen preparation (Nolvadex) was discontinued and patients were since gradually switched to alternative generic tamoxifen brands. The goal of this study is to evaluate factors affecting adjuvant tamoxifen related side effects and compliance including altering tamoxifen products. Methods: Consecutive patients treated for ER positive breast cancer (stage I-III) in the Royal Hampshire County Hospital between January 1, 2007 and December 31, 2009 were included. 327 questionnaires were sent to eligible patients. Pearson芒�?�?s 脧�?2 test was used for data analysis. Results: 59% of patients experienced side effects associated with tamoxifen treatment out of which 53% were severe. Switching to generic tamoxifen was associated with more severe side effects (p=0.02). Non-prescribed supplements were taken by 42% of symptomatic patients with no significant improvement (p=0.05). Interestingly, the concomitant use of SSRI had no effect on side effects experienced by patients. A significant number of patients considered discontinuing tamoxifen because of the side effects (p=0.001), yet this did not translate into tamoxifen discontinuation or non adherence (p=0.8 and 0.08 respectively). Conclusions: Severe tamoxifen side effects are commonly experienced by breast cancer patients and are altered by change in tamoxifen brand. Most patients will continue to take tamoxifen despite these side effects following clinicians芒�?�? advice to avoid cancer relapse. Supplementation and antidepressants did not improve tamoxifen related side effects. Further studies are needed to validate our preliminary findings.Biography
Bashar Zeidan is a Clinical Lecturer in Surgery at the University of Southampton. He has a special interest in breast cancer research and oncoplastic breast surgery. He was awarded the first UK Academic Clinical Fellowship in Surgery in 2007. Following his fellowship he completed a higher degree focusing on breast cancer research and was granted a Doctorate of Philosophy Degree from the University of Southampton in 2013. He is an author of more than 15 papers and 2 book chapters in the field of surgery.
Email: bashar.zeidan@hhft.nhs.uk
